[ABO-incompatible kidney transplantation].
Nakagawa
Yuki
Y
Division of Urology, Department of Regenerative and Transplant Medicine, Graduate School of Medical and Dental Sciences, Niigata University.
Saito
Kazuhide
K
Takahashi
Kota
K
D000017:ABO Blood-Group System / Q000276:immunology; D000906:Antibodies / Q000302:isolation & purification; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D058846:Antibodies, Monoclonal, Murine-Derived; D000917:Antibody Formation / Q000187:drug effects; D000925:Anticoagulants / Q000627:therapeutic use; D000077552:Basiliximab; D001787:Blood Group Incompatibility / Q000276:immunology*; D004359:Drug Therapy, Combination; D006084:Graft Rejection / Q000517:prevention & control*; D007163:Immunosorbent Techniques; D007166:Immunosuppressive Agents / Q000008:administration & dosage; D016030:Kidney Transplantation / Q000276:immunology* / Q000639:trends; D010951:Plasma Exchange; D010956:Plasmapheresis / Q000379:methods; D011379:Prognosis; D011993:Recombinant Fusion Proteins / Q000008:administration & dosage; D000069283:Rituximab; D016559:Tacrolimus / Q000008:administration & dosage
D000017:ABO Blood-Group System; D000906:Antibodies; D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000925:Anticoagulants; D007166:Immunosuppressive Agents; D011993:Recombinant Fusion Proteins; D000069283:Rituximab; D000077552:Basiliximab; D016559:Tacrolimus